Arcturus Therapeutics Holdings - Stock Price History | ARCT

Historical daily share price chart and data for Arcturus Therapeutics Holdings since 2021 adjusted for splits. The latest closing stock price for Arcturus Therapeutics Holdings as of September 27, 2021 is 50.13.
  • The all-time high Arcturus Therapeutics Holdings stock closing price was 178.52 on October 07, 2013.
  • The Arcturus Therapeutics Holdings 52-week high stock price is 129.71, which is 158.7% above the current share price.
  • The Arcturus Therapeutics Holdings 52-week low stock price is 24.87, which is 50.4% below the current share price.
  • The average Arcturus Therapeutics Holdings stock price for the last 52 weeks is 51.49.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Arcturus Therapeutics Holdings Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 41.4092 10.0000 123.6600 9.3100 43.3800 299.08%
2019 8.4762 4.6900 14.5000 4.4200 10.8700 139.96%
2018 6.9613 7.9900 9.8000 4.1100 4.5300 -43.02%
2017 8.4524 15.4654 17.6347 6.5598 7.9500 -45.90%
2016 28.1334 43.6669 44.7166 12.5962 14.6956 -66.56%
2015 46.8823 26.6620 64.5906 26.6620 43.9468 68.36%
2014 107.2062 124.9825 175.0875 22.5332 26.1022 -79.28%
2013 97.1120 52.8341 178.5164 46.4661 125.9622 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.320B $0.010B
Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29